Author

Alexandr V. Yurkovetskiy

Institution: Mersana Therapeutics (United States)

Observed institution: Mersana Therapeutics (United States)

ORCID: 0009-0005-9075-7799

Observed ORCID: 0009-0005-9075-7799

OpenAlex ID: A5111035913

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

2023 · Dorin Toader, Shawn P. Fessler, et al. · Molecular Cancer Therapeutics · 45

Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

2023 · Dorin Toader, Shawn P. Fessler, et al.

Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

2023 · Dorin Toader, Shawn P. Fessler, et al.

Works count: 3

Citation count: 45

H-index: 1

I10-index: 1